<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0208245719
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        M.M.R II 0.5ML VACCINE+ 0.7ML DILUENT
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MEASLES VIRUS (SCHWARZ) LIVE ATTENUATED,MUMPS VIRUS (JERYL LYNN, STRAIN RIT 4385) LIVE ATTENUATED,RUBELLA VIRUS (WISTAR RA 27/3) LIVE ATTENUATED
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1000,12.5,1000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        51.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MERCK SHARP AND DOHME LLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MERCK SHARP AND DOHME LLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SHARP AND DOHME LLC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07BD52
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>M.M.R II is a vaccine containing measles, mumps, and rubella viruses that have been weakened. When a person is given the vaccine, the immune system (the body&#39;s natural defences) will make antibodies against the measles, mumps, and rubella viruses. The antibodies help protect against infections caused by these viruses.</p><p>&nbsp;</p><p>M.M.R II is given to help protect you or your child against measles, mumps, and rubella. The vaccine may be administered to persons 12 months of age or older.</p><p>M.M.R II can &nbsp;be &nbsp;administered &nbsp;to &nbsp;infants &nbsp;from &nbsp;9 &nbsp;to &nbsp;12 &nbsp;months &nbsp;of &nbsp;age &nbsp;under &nbsp;special circumstances.</p><p>&nbsp;</p><p>M.M.R II can also be used in measles outbreaks, or for post-exposure vaccination, or for use in previously unvaccinated persons older than 9 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella.</p><p>&nbsp;</p><p>Although M.M.R II contains live viruses, they are too weak to cause measles, mumps, or rubella in healthy people.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use M.M.R II:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the person to be vaccinated is allergic to any measles, mumps or rubella vaccine or to any of the ingredients of this vaccine (listed in section 6) including neomycin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the person to be vaccinated is pregnant (in addition, pregnancy should be avoided for 1 month after vaccination, see Pregnancy and breast-feeding)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the person to be vaccinated has any illness with fever higher than 38.5 &deg;C; however, low-grade fever itself is not a reason to delay vaccination</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the person to be vaccinated has active untreated tuberculosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the person to be vaccinated has a blood disorder or any type of cancer that affects the immune system</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the person to be vaccinated is receiving treatment or taking medicines that may weaken the immune system (except low-dose corticosteroid therapy for asthma or replacement therapy)</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the person to be vaccinated has a weakened immune system because of a disease (including AIDS)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the person to be vaccinated has a family history of congenital or hereditary immunodeficiency, unless the immune competence of the person to be vaccinated is demonstrated.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to the doctor or pharmacist before the person to be vaccinated receives M.M.R II if he/she has experienced any of the following:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an allergic reaction to eggs or anything that contained egg</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a history or family history of allergies or of convulsions (fits)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a side effect after vaccination with measles, mumps and/or rubella vaccine that involved easy bruising or bleeding for longer than usual</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an infection with Human Immunodeficiency Virus (HIV) but do not show symptoms of HIV disease. The vaccinated person should be monitored closely for measles, mumps and rubella because vaccination may be less effective than for uninfected persons (see section <strong>Do not use M-MR II</strong>).</p><p>&nbsp;</p><p>As with other vaccines, M.M.R II may not completely protect all persons who are vaccinated. Also, if the person who is to be vaccinated has already been exposed to the measles, mumps, or rubella virus but is not yet ill, M.M.R II may not be able to prevent the illness from appearing.</p><p>&nbsp;</p><p>M.M.R II can be given to persons who have been in recent (within 3 days) contact with a case of measles and may be incubating the disease. However, M.M.R II may not always be able to prevent measles developing in these cases.</p><p>&nbsp;</p><p><strong>Other medicines and M.M.R II </strong></p><p>Tell your doctor or pharmacist if the person to be vaccinated is taking or has recently taken any other medicines (or other vaccines).</p><p>&nbsp;</p><p>The doctor may delay vaccination for at least 3 months following blood or plasma transfusions, or administration of immune globulin (known as IG). After vaccination with M.M.R II, IG should not be given for 1 month, unless your doctor tells you otherwise.</p><p>&nbsp;</p><p>If a tuberculin test is to be performed, it should be done either any time before, simultaneously with, or</p><p>4 to 6 weeks after vaccination with M.M.R II.</p><p>&nbsp;</p><p>M.M.R II may be given with a pneumococcal conjugate vaccine and/or hepatitis A vaccine at the same visit at a separate injection site (e.g. the other arm or leg).</p><p>&nbsp;</p><p>M.M.R II may be given with some routine childhood vaccines that may be due to be given at the same time. For vaccines that cannot be given at the same time, M.M.R II should be given 1 month before or after administration of those vaccines.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>M.M.R II should not be given to pregnant females. Females of child-bearing age should take the necessary precautions to avoid pregnancy for 1 month, or according to doctor&rsquo;s recommendation, after they have been given the vaccine.</p><p>&nbsp;</p><p>Persons who are breast-feeding or intend to breast-feed should tell the doctor. The doctor will decide if</p><p>M.M.R II should be given.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this vaccine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>There is no information to suggest that M.M.R II affects the ability to drive or operate machinery.</p><p>&nbsp;</p><p>M.M.R II contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 milligrams) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p>M.M.R II contains potassium</p><p>This medicine contains less than 1 mmol potassium (39 milligrams) per dose, that is to say essentially &lsquo;potassium-free&rsquo;.</p><p>&nbsp;</p><p>M.M.R II contains sorbitol (E 420)</p><p>This medicine contains 14.5 milligrams of sorbitol per dose. The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>M.M.R II should be injected into the muscle or under the skin either in the area of the outer thigh or of the upper arm. Usually for injections into the muscle the thigh area is preferred in young children whereas for older individuals the upper arm area is the preferred injection site. M.M.R II &nbsp;is not to be injected directly into any blood vessel.</p><p>&nbsp;</p><p>M.M.R II is given as follows:</p><p>One dose is given at an elected date usually from 12 months of age. &nbsp;Under special circumstances, it can be given from 9 months of age. Further doses should be administered according to your doctor&rsquo;s recommendation. The interval between 2 doses should be at least 4 weeks.</p><p>&nbsp;</p><p>Reconstitution instructions intended for medical and healthcare professionals are included at the end of the package leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all vaccines and medicines, this vaccine can cause side effects, although not everybody gets them. The following side effects were reported with the use of M.M.R II:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:1.5in"><p>Frequency</p></td><td style="border-color:black; height:25.8pt; vertical-align:top; width:347.15pt"><p>Side effect</p></td></tr><tr><td style="border-color:black; height:38.5pt; vertical-align:top; width:1.5in"><p>Very common (may affect more than 1 in 10 vaccinees)</p></td><td style="height:38.5pt; vertical-align:top; width:347.15pt"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Fever (38.5&deg;C or higher).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Injection-site redness; injection-site pain; injection-site swelling.</p></td></tr><tr><td style="border-color:black; height:39.95pt; vertical-align:top; width:1.5in"><p>Common (may affect 1 to 10 in 100 vaccinees)</p></td><td style="height:39.95pt; vertical-align:top; width:347.15pt"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Rash (including measles-like rash).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Injection-site bruising.</p></td></tr><tr><td style="border-color:black; height:84.85pt; vertical-align:top; width:1.5in"><p>Uncommon (may affect 1 to 10 in 1000 vaccinees)</p></td><td style="height:84.85pt; vertical-align:top; width:347.15pt"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Nasal congestion and sore throat<em>;</em><em> </em>upper respiratory tract infection or viral infection; runny nose.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Diarrhoea, vomiting.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Hives.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Injection-site rash.</p></td></tr><tr><td style="border-color:black; height:473.2pt; vertical-align:top; width:1.5in"><p>Not known (Frequency cannot be estimated from the available data)*</p></td><td style="height:473.2pt; vertical-align:top; width:347.15pt"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Aseptic meningitis (fever, feeling sick, vomiting, headache, stiff neck, and sensitivity to light); swollen testicles; infection of the middle ear<em>;</em><em> </em>inflamed salivary glands; atypical measles (described in patients who received a killed measles virus vaccine, usually given before 1975).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Swollen lymph nodes.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Bruising or bleeding more easily than normal<em>.</em></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Severe allergic reaction that may include difficulty in breathing, facial swelling, localised swelling, and swelling of the limbs.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Irritability.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Seizures (fits) without fever; seizures (fits) with fever in children; walking unsteadily; dizziness; illnesses involving inflammation of the nervous system (brain and/or spinal cord).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->An illness consisting of muscle weakness, abnormal sensations, tingling in the arms, legs, and upper body (Guillain-Barr&eacute; syndrome).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Headache; fainting; nerve disorders which can cause weakness, tingling, or numbness; eye nerve disturbances.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Discharge and itching of the eyes with crusting of eyelids (conjunctivitis).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Inflammation of the retina (in the eye) with changes in sight.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Deafness.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Cough; lung infection with or without fever.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Feeling sick (nausea).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Itching; inflammation of the fatty tissue under the skin; red or purple, flat, pinhead spots under the skin; hardened, raised area of the skin; serious illness with ulcers or blistering of the skin, mouth, eyes, and/or genitals (Stevens-Johnson syndrome).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Joint pain and/or swelling (usually transient and rarely chronic); muscle pain.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Burning and/or stinging of short duration at the injection site; blisters and/or hives at the injection site.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Generally feeling unwell (malaise); swelling; soreness.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Inflammation of blood vessels.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>*These side effects were reported with the use of M.M.R II or with the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc., or with its monovalent (single) components, during post-marketing use and/or during clinical studies.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects</p><p>not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance and Drug Safety Centre (NPC), SFDA. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this vaccine after the expiry date which is stated on the outer carton after EXP. The expiry date is written on both outer carton &amp; inner label.</p><p>&nbsp;</p><p>Store and transport refrigerated (2 &deg;C - 8 &deg;C).</p><p>Keep the vial of powder in the outer carton in order to protect from light.</p><p>Do not freeze the vaccine.</p><p>&nbsp;</p><p>Do not throw away any vaccines via wastewater or household waste. Ask your pharmacist how to throw away vaccines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What M.M.R II contains</strong></p><p>&nbsp;</p><p>The active substances are:</p><p>&nbsp;</p><p>After reconstitution, one dose (0.5 mL) contains:</p><p>&nbsp;</p><p>Measles virus<sup>1</sup> Enders&rsquo; Edmonston strain (live, attenuated)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not less than 1x10<sup>3</sup> TCID<sub>50</sub>* Mumps virus<sup>1</sup> Jeryl Lynn&trade; [Level B] strain (live, attenuated)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not less than 12.5x10<sup>3</sup> TCID<sub>50</sub>* Rubella virus<sup>2</sup> Wistar RA 27/3 strain (live, attenuated)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not less than 1x10<sup>3</sup> TCID<sub>50</sub>*</p><p>&nbsp;</p><p>* 50% tissue culture infectious dose</p><p><sup>1</sup> produced in chick embryo cells.</p><p><sup>2</sup> produced in WI-38 human diploid lung fibroblasts. The other ingredients are:</p><p><u>Powder:</u></p><p>Sorbitol (E 420), sodium phosphate (NaH<sub>2</sub>PO<sub>4</sub>/Na<sub>2</sub>HPO<sub>4</sub>), potassium phosphate (KH<sub>2</sub>PO<sub>4</sub>/K<sub>2</sub>HPO<sub>4</sub>), sucrose, hydrolysed gelatine, medium 199 with Hanks&rsquo; salts, MEM, monosodium L-glutamate, neomycin, phenol red, sodium bicarbonate (NaHCO<sub>3</sub>), hydrochloric acid (HCl) (to adjust pH), and sodium hydroxide (NaOH) (to adjust pH)</p><p>&nbsp;</p><p><u>Solvent:</u></p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What M.M.R II looks like and contents of the pack

The vaccine is a powder for suspension for injection contained in a single-dose vial, which should be mixed with solvent provided.

The solvent is a clear and colourless liquid. The powder is a light yellow compact crystalline cake. 
M.M.R II is available in packs of 1 and 10. Not all pack sizes may be marketed. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder:</strong></p><p>Merck, Sharp &amp; Dohme LLC, 770 Sumneytown Pike, P.O. Box 4, West Point, PA 19486, US.</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Merck, Sharp &amp; Dohme LLC, 770 Sumneytown Pike, P.O. Box 4, West Point, PA 19486, US.</p><p>&nbsp;</p><p><u>And/ Or</u></p><p>&nbsp;</p><p>Merck, Sharp &amp; Dohme LLC, 5325 Old Oxford Road, Durham, NC 27712, US</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised on Dec 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>(إم.إم.آر 2) هو لقاح يحتوي على فيروسات الحصبة والنكاف والحصبة الألمانية المُضعّفة. عند إعطاء اللقاح لشخصٍ ما، يقوم الجهاز المناعي لديه (الدفاعات الطبيعية في الجسم) بإنتاج أجسام مضادة لفيروسات الحصبة والنكاف والحصبة الألمانية. تساعد الأجسام المضادة في الوقاية من الالتهابات التي تسببها هذه الفيروسات.</p><p>يتم إعطاء (إم.إم.آر 2) للمساعدة في حمايتك أو حماية طفلك من الإصابة بالحصبة والنكاف والحصبة الألمانية. يمكن إعطاء اللقاح للأطفال بدءًا من عمر 12 شهرا وما فوق.</p><p>كما يمكن إعطاء (إم.إم.آر 2) للأطفال الرضّع الذين تتراوح أعمارهم من 9-12 شهراً في ظل ظروف خاصة.</p><p>ويمكن إعطاء (إم.إم.آر 2) في حالات تفشي مرض الحصبة، أو للوقاية بعد التعرض للمرض، أو لتطعيم الرضع ممن تجاوزوا 9 شهور من العمر ولم يتم تلقيحهم في السابق وهم يختلطون بالنساء الحوامل المعرّضات للإصابة بالعدوى، وكذلك لتطعيم الأشخاص الذين يُحتمل أن يكونوا عرضة للإصابة بالنكاف والحصبة الألمانية.</p><p>على الرغم من أن (إم.إم.آر 2) يحتوي على فيروسات حية، إلا أنها ضعيفة جدا بحيث لا تُسبب الحصبة أو النكاف أو الحصبة الألمانية لدى الأشخاص الأصحاء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتلقَّ (إم.إم.آر 2) إذا :</strong><br />-&nbsp;&nbsp; إذا كان لدى الشخص الذي سيتلقى اللقاح حساسية نحو لقاح الحصبة والنكاف والحصبة الألمانية أو أي من مكونات هذا اللقاح (بما فى ذلك النيوميسين أو أى من&nbsp; المكونات الأخرى المدرجة فى الفقرة رقم 6)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كان الشخص الذي سيتلقى اللقاح حامل (بالإضافة إلى ذلك، ينبغي تجنب الحمل لمدة&nbsp; شهر بعد التطعيم، انظر فقرة الحمل والرضاعة الطبيعية)</p><p dir="RTL">- &nbsp;&nbsp;&nbsp;إذا كان لدى الشخص الذي سيتلقى اللقاح مصاب بمرض مصحوب بحمى تتجاوز 38.5 درجة مئوية. ومع ذلك، فإن وجود الحمى منخفضة الدرجة في حد ذاته لا يُعد سببًا لتأخير التطعيم</p><p dir="RTL">- &nbsp;&nbsp;&nbsp;إذا كان لدى الشخص الذي سيتلقى اللقاح مصابًا بمرض السلّ غير المعالج</p><p dir="RTL">-&nbsp;&nbsp; &nbsp;إذا كان لدى الشخص الذي سيتلقى اللقاح مصابًا باضطراب في الدم أو أي نوع من أنواع السرطان التي تؤثر على الجهاز المناعي</p><p dir="RTL">- &nbsp;&nbsp;&nbsp;إذا كان لدى الشخص الذي سيتلقى اللقاح يتلقى علاجًا أو يتناول الأدوية التي قد تضعف جهاز المناعة (باستثناء الجرعة المنخفضة من دواء كورتيكوستيرويد التي تُستخدم في علاج الربو أو العلاج بالاستعاضة)</p><p dir="RTL">- &nbsp;&nbsp;&nbsp;إذا كان لدى الشخص الذي سيتلقى اللقاح ضعف في جهاز المناعة بسبب الإصابة بمرض (بما في ذلك الإيدز)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كان لدى الشخص الذي سيتلقى اللقاح تاريخ عائلي من نقص المناعة الخَلقي أو الوراثي، إلا إذا أُثبتت كفاءة الجهاز المناعي لديك أو لدى طفلك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">تحدث إلى الطبيب أو الصيدلي قبل أن يتلقى الشخص الذي يأخذ اللقاح (إم.إم.آر 2) إذا واجهت أي مما يلي:<br />-&nbsp;&nbsp;&nbsp; رد فعل تحسسي نحو البيض أو نحو أي مادة تحتوي على البيض<br />-&nbsp;&nbsp; &nbsp;وجود تاريخ شخصي أو عائلي من الحساسية أو التشنجات (النوبات)<br />-&nbsp;&nbsp; &nbsp;حدوث أثر جانبي يتضمن سهولة التكدّم أو نزيف لفترة أطول من المعتاد وذلك بعد تلقيك لقاح الحصبة أو النكاف أو الحصبة الألمانيّة</p><p dir="RTL">- &nbsp;&nbsp;&nbsp;الاصابة بفيروس نقص المناعة البشرية (إش آي في HIV) ولكن دون ظهور أعراض مرض نقص المناعة البشرية. عندها يجب أن يخضع الشخص الذي تلقى اللقاح للمراقبة عن كثب تحسبًا لظهور الحصبة والنكاف والحصبة االألمابيّة لأن التطعيم قد يكون أقل فعالية في هذه الحالة مقارنة بما هو عليه لدى الأشخاص غير المصابين (انظر فقرة <strong>لا تستخدم (إم.إم.آر 2)</strong>).</p><p dir="RTL">وكما هو الحال مع اللقاحات الأخرى، قد لا يحمي (إم.إم.آر 2) تمامًا جميع الأشخاص الذين يتلقونه. وكذلك، إذا كان الشخص الذي سيتلقّى اللّقاح قد تعرّض بالفعل لفيروس الحصبة، أو النكاف، أو الحصبة الألمانية ولكن لم تظهر عليه الأعراض بعد، فقد لا يكون (إم.إم.آر 2) قادرًا على منع ظهور المرض &nbsp;لديه.</p><p dir="RTL">ويمكن إعطاء (إم.إم.آر 2) للأشخاص الذين اختلطوا مع أحد المرضى المصابين بالحصبة مؤخرًا (في غضون 3 أيام) ومن المحتمل أن يكونوا قد بدؤوا في فترة احتضان المرض. ولكن، قد لا يكون (إم.إم.آر 2) دائمًا قادرًا على منع حدوث الحصبة في هذه الحالات.</p><p dir="RTL"><strong>أدوية أخرى ولقاح (إم.إم.آر 2)</strong><br />أخبر طبيبك أو الصيدلي إذا كان الشخص الذي سيتلقى اللقاح يتناول أو تناول مؤخرًا أي أدوية أخرى (أو لقاحات أخرى).<br />قد يلجأ الطبيب إلى تأخير التطعيم بلقاح (إم.إم.آر 2) 3 أشهر على الأقل بعد إجراء نقل الدم أو البلازما أو تلقّي الجلوبولين المناعي (الذي يُعرف أيضًا أي جي IG)، كما ينبغي تجنّب إعطاء IG لمدة شهر بعد تلقي لقاح (إم.إم.آر 2) ما لم ينصح الطبيب بخلاف ذلك.</p><p dir="RTL">إذا كان لا بد من إجراء اختبار السلّ، ينبغي أن يتم ذلك في أي وقت قبل، في نفس الوقت مع، أو بعد التطعيم بلقاح (إم.إم.آر 2) بمدة 4-6 أسابيع.</p><p dir="RTL">يمكن إعطاء (إم.إم.آر 2) مع لقاح بريفينار و / أو التهاب الكبد أ خلال نفس الزيارة في موضع حقن منفصل (على سبيل المثال الذراع أو الساق الأخرى).</p><p dir="RTL">يمكن إعطاء (إم.إم.آر 2) مع بعض اللقاحات الروتينية للأطفال والتي يحين موعد إعطاؤها في نفس وقت إعطاؤه. بالنسبة للقاحات التي لا يمكن إعطاءها في نفس الوقت، يجب إعطاء (إم.إم.آر 2) قبل أو بعد إعطاء تلك اللقاحات بمدة شهر واحد.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا ينبغي إعطاء (إم.إم.آر 2) للحوامل. يجب على النساء ممن هنّ في سنّ الإنجاب اتخاذ الاحتياطات اللازمة لتجنب الحمل لمدة شهر واحد بعد تلقّي اللقاح، أو وفقًا لتوصية الطبيب.</p><p dir="RTL">يجب على السيدات اللاتي يقمن بالرضاعة الطبيعية أو لديهن النيّة للقيام بذلك &nbsp;إخبار الطبيب قبل تلقي اللقاح. سوف يقرر الطبيب إذا كان ينبغي إعطاء (إم.إم.آر 2) من عدمه.</p><p dir="RTL">استشيري طبيبك أو الصيدلي قبل تلقي هذا اللقاح إذا كنت حاملًا أو مرضعًا، تعتقدين أنك ربما تكونين حاملًا، أو تخططين للحمل.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><br />لا توجد معلومات تشير إلى أن (إم.إم.آر 2) يؤثر على القدرة على القيادة أو تشغيل الآلات.</p><p dir="RTL"><strong>(إم.إم.آر 2) يحتوي على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم ( 23 ملليغرام) &nbsp;لكل جرعة ، أي &quot;خالٍ من الصوديوم&quot;.</p><p dir="RTL"><strong>(إم.إم.آر 2) يحتوي على البوتاسيوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول بوتاسيوم ( 39 ملليغرام) &nbsp;لكل جرعة ، أي &quot;خالٍ من البوتاسيوم &quot;.</p><p dir="RTL"><strong>(إم.إم.آر 2) يحتوي على السورباتول (إي 420)</strong><br />هذا الدواء يحتوي على 14,5 &nbsp;ملليغرام من سوربيتول لكل جرعة. وينبغي أن يؤخذ في الاعتبار الأثر الإضافي للمنتجات التي تُعطى سوية والتي تحتوي على سوربيتول أو &nbsp;(الفركتوز ) وتناول السيوربيتول أو( الفركتوز)</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب حقن (إم.إم.آر 2) في العضل أو تحت الجلد إما في المنطقة الخارجية من الفخذ أو في الجزء العلوي من الذراع. يُفضّل عادة عند الحقن في العضل استخدام منطقة الفخذ عند الأطفال الصغار في حين تعتبر المنطقة العليا من الذراع موضع الحقن المفضل بالنسبة للأشخاص الأكبر سنا. لا ينبغي حقن (إم.إم.آر 2) مباشرة في أي وعاء دموي.</p><p>ويُعطى (إم.إم.آر 2) على النحو التالي:<br />يتم إعطاء جرعة واحدة في التاريخ الذي يتم اختياره بدءًا من عمر 12 شهرا عادةً،&nbsp; وفي ظل ظروف خاصة، يمكن إعطاؤه بدءًا من عمر 9 أشهر. وينبغي إعطاء الجرعات الأخرى وفقا لتوصية الطبيب. وينبغي أن يكون الفاصل الزمني بين كل جرعتين 4 أسابيع على الأقل.</p><p>تم إدراج التعليمات الخاصة بإعادة تشكيل المسحوق على هيئة محلول والموجهة للمتخصصين في الرعاية الصحية في نهاية هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>يمكن أن يُسبّب هذا اللقاح آثارًا جانبيّة، كما هو الحال مع جميع الأدوية واللقاحات، وإن كانت لا تحدث لدى جميع من يتلقاه.<br />تم الإبلاغ عن الآثار الجانبية التالية مع استخدام (إم.إم.آر 2):</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:184.25pt"><p>تكرار الحدوث</p></td><td style="vertical-align:top; width:283.25pt"><p>الآثار الجانبيّة</p></td></tr><tr><td style="vertical-align:top; width:184.25pt"><p>شائعة جدًا (قد تؤثر على أكثر من شخص من بين 10 ممن تلقّوا اللقاح)</p></td><td style="vertical-align:top; width:283.25pt"><p>&bull; حمى (38.5 درجة مئوية أو أكثر)</p><p>&bull; احمرار، ألم، تورّم موضع الحقن.</p></td></tr><tr><td style="vertical-align:top; width:184.25pt"><p>شائعة (قد تؤثر على 1-10 أشخاص من بين 100 ممن تلقّوا اللقاح)</p></td><td style="vertical-align:top; width:283.25pt"><p>&bull; طفح جلدي (يشمل الطفح الشبيه بالحصبة)</p><p>&bull; ظهور كدمات في موضع الحقن.</p></td></tr><tr><td style="vertical-align:top; width:184.25pt"><p>غير شائعة (قد تؤثر على 1-10 أشخاص من بين 1000 ممن تلقّوا اللقاح)</p></td><td style="vertical-align:top; width:283.25pt"><p>&bull; احتقان الأنف والتهاب الحلق؛ عدوى الجهاز التنفسي<br />&nbsp; العلوي أو عدوى فيروسية؛ سيلان الأنف.</p><p>&bull; الإسهال والتقيؤ.</p><p>&bull; الشرى.</p><p>&bull; الطفح الجلدي في موضع الحقن.</p></td></tr><tr><td style="vertical-align:top; width:184.25pt"><p>غير معروف (لا يمكن تقدير التكرار من البيانات المتاحة) *</p></td><td style="vertical-align:top; width:283.25pt"><p>&bull; التهاب السحايا العقيم (الحمّى، والشعور بالمرض،<br />&nbsp; والتقيؤ، والصداع، وتيبُّس الرقبة، والحساسية نحو<br />&nbsp; الضوء)؛ تورّم الخصيتين؛ التهاب الأذن الوسطى<br />&nbsp; الجرثومي؛ التهاب الغدد اللعابية؛ الحصبة غير النمطية<br />&nbsp; (الموصوفة في المرضى الذين تلقوا لقاح فيروس الحصبة<br />&nbsp; المقتول، &nbsp;&nbsp;والذي كان يُستخدم قبل عام 1975م).</p><p>&bull; تورم الغدد الليمفاوية.</p><p>&bull; التكدّم أو النزيف بسهولة أكثر من المعتاد.</p><p>&bull; رد فعل تحسسي شديد قد يتضمن صعوبة في التنفس،<br />&nbsp; وتورم في الوجه، وتورم موضعي، وتورم في الأطراف.</p><p>&bull; الهيجان.<br />&bull; التشنجات (النوبات) دون حمى؛ التشنجات (النوبات)<br />&nbsp; المصحوبة بحمّى لدى الأطفال؛ المشي بشكل غير ثابت؛<br />&nbsp; دوخة؛ الأمراض التي تنطوي على التهاب الجهاز<br />&nbsp; العصبي (الدماغ و / أو الحبل الشوكي).</p><p>&bull; مرض يتكون من ضعف العضلات، والأحاسيس الشاذة،<br />&nbsp; ووخز في الذراعين والساقين والجزء العلوي من الجسم<br />&nbsp; (متلازمة غيلان باريه).</p><p>&bull; صداع؛ إغماء؛ الاضطرابات العصبية التي يمكن أن<br />&nbsp; تسبب الضعف، وخز، أو خدر؛ اضطرابات عصب<br />&nbsp; العين.</p><p>&bull; خروج إفرازات من العينين والحكة&nbsp; مع تقشّر الجفنين<br />&nbsp;&nbsp;(التهاب الملتحمة).</p><p>&bull; التهاب الشبكية (في العين) مع تغيرات في الإبصار.</p><p>&bull; الصمم.</p><p>&bull; سعال؛ التهاب الرئة مع أو بدون حمى.</p><p>&bull; الشعور بالمرض (الغثيان).<br />&bull; الحكّة؛ التهاب الأنسجة الدهنية تحت الجلد؛ ظهور بقع<br />&nbsp; حمراء أو أرجوانية، مُسطّحة، بحجم رأس الدبوس تحت<br />&nbsp; الجلد؛ ظهور مناطق مرتفعة ومتصلبة في الجلد؛ مرض<br />&nbsp; خطير مع تكوّن التقرحات أو البثور في الجلد، الفم،<br />&nbsp; العينين، و / أو الأعضاء التناسلية (متلازمة ستيفنز<br />&nbsp; جونسون).</p><p>&bull; آلام المفاصل و / أو تورمها (تكون عادة عابرة ونادرا ما تُصبح مزمنة)؛ ألم عضلي.</p><p>&bull; الشعور بالحرقة و / أو الوخز لفترة قصيرة في موضع<br />&nbsp; الحقن: بثور و / أو الشرى في موضع الحقن.</p><p>&bull; الشعور العام بالتوعك (الشعور بالضيق). تورم؛ وجع.</p><p>&bull; التهاب الأوعية الدموية.</p></td></tr></tbody></table><p>* تم الإبلاغ عن هذه الآثار الجانبية مع استخدام (إم.إم.آر 2) أو مع لقاح الحصبة والنكاف والحصبة الألمانية المُصنّع من قبل شركة ميرك وشركاه، أو مع مكوناته أحادية التكافؤ ( مكوّن واحد)، خلال مرحلة ما بعد التسويق و / أو خلال الدراسات السريرية.</p><p><strong>الإبلاغ عن الآثار الجانبية</strong></p><p>إذا تعرّضت لأي آثار جانبية، تحدث مع طبيبك أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. یمکنك أیضا الإبلاغ عن الآثار الجانبیة مباشرة من خلال المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء &nbsp;. إبلاغك عن الآثار الجانبیة یساعد في توفیر المزید من المعلومات حول سلامة هذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ هذا اللقاح بعيدا عن مرأى ومتناول الأطفال.<br />لا تستخدم هذا اللقاح بعد تاريخ انتهاء الصلاحية المدوّن على العلبة من الخارج بعد (EXP). تاريخ انتهاء الصلاحية مدوّن على الملصق الداخلي و العبوة الخارجية.<br />يُحفظ مُبرداً أثناء التخزين والنقل (2 درجة مئوية -8 درجة مئوية).<br />احتفظ بالقارورة التي تحتوي على المسحوق في الكرتون الخارجي من أجل حمايته من الضوء.<br />لا تُجمّد اللقاح.</p><p>يجب استخدام اللقاح بعد خلطه مع المذيب المتوفر معه، إما على الفور أو في غضون 8 ساعات مع الحفاظ على تخزينه في الثلاجة خلال هذه المدة.</p><p>لا تتخلص من أي لقاحات عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من اللقاحات التي لم تعد تستخدمها. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ماذا يحتوي لقاح (إم.إم.آر 2)</strong><br />المواد الفعالة هي:</p><p>بعد اعادة تشكيل المسحوق, الجرعه الواحده (0.5 مل ) تحتوي على:<br />فيروس الحصبة<sup>1</sup> سلالة إندرز إدمونستون (حيّ، مُضعّف)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;لا يقل عن 1 &times; <sup>3</sup>10 CCID50*<br />فيروس النّكاف<sup>1</sup> سلالة جيريل لين<sup>TM</sup> [مستوى ب] (حيّ، مُضعّف)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يقل عن 12.5 &times; <sup>3</sup>10 CCID50*<br />فيروس الحصبة الألمانيّة<sup>2</sup> سلالة ويستار أر إيه 3/27(حيّ، مُضعّف)&nbsp; لا يقل عن 1 &times; <sup>3</sup>10 CCID50*</p><p>*: 50% الجرعة المُعدية للمزرعة الخلوية<br /><sup>1</sup>: أُنتج في خلايا جنين الفرخ<br /><sup>2</sup>: أُنتج في خلايا الرئة الليفيّة البشرية WI-38</p><p>المكونات الأخرى هي:<br /><u>المسحوق:</u><br />الجيلاتين المائي (5&sbquo; 14 ملغم)</p><p>المتوسط 199 مع أملاح هانكس (3&sbquo; 3 ملغم)</p><p>المتوسطة الأساسي الأدنى (1&sbquo; 0 ملغم)</p><p>إل-غلوتامات أحادي الصوديوم (20 ميكروغرام)</p><p>نيوميسين (25 ميكروغرام)</p><p>الفينول الأحمر (4&sbquo;3 ميكروغرام)</p><p>فوسفات البوتاسيوم لا مائي، ثنائي القاعدة (30 ميكروغرام)</p><p>فوسفات البوتاسيوم، احادي القاعدة (20 ميكروغرام)</p><p>بيكربونات الصوديوم (5&sbquo; 0 ملغم)</p><p>فوسفات الصوديوم لا مائي، ثنائي القاعدة (2&sbquo; 2 ملغم)</p><p>فوسفات الصوديوم، احادي القاعدة (1&sbquo; 3 ملغم)</p><p>سوربيتول (5&sbquo; 14 ملغم)</p><p>سكروز (9&sbquo; 1 ملغم)</p><p>حمض الهيدروكلوريك (لضبط درجة الحموضة)</p><p>هيدروكسيد الصوديوم (لضبط درجة الحموضة )</p><p>&nbsp;</p><p><u>المُذيب</u><br />ماء مُخصّص للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يتكون اللقاح من مسحوق للحل على هيئة مُعلّق للحقن ، محفوظ في قارورة تحتوي على جرعة واحدة، وينبغي خلط المسحوق مع المذيب المترافق معه في العلبة. المذيب هو سائل صافٍ وعديم اللون. مسحوق اللقاح عبارة عن كتلة بلورات متراصة، لونه أصفر . إم إم آر 2 متوفر في عُلب تحتوي على 1- 10 قوارير. قد لا تُسوّق جميع أحجام العبوة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل رخصة التسويق و الشركة المُصنّعة</strong></p><p dir="RTL"><strong>حامل رخصة التسويق</strong></p><p dir="RTL">شركة ميرك شارب و دوهم ذ م م</p><p dir="RTL">770 سومنيتون بايك</p><p dir="RTL">ص ب 4</p><p dir="RTL">ويست بوينت، بي إيه 19486، الولايات المُتحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المُصنّعة</strong></p><p dir="RTL">شركة ميرك شارب و دوهم ذ م م</p><p dir="RTL">770 سومنيتون بايك</p><p dir="RTL">ص ب 4</p><p dir="RTL">ويست بوينت، بي إيه 19486، الولايات المُتحدة</p><p dir="RTL"><strong>و/أو</strong></p><p dir="RTL">شركة ميرك شارب و دوهم ذ م م</p><p dir="RTL">5325 طريق أولد أوكسفورد</p><p dir="RTL">دورهام، إن سي 27712، الولايات المتحدة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت أخر مُراجعة لهذه النشرة بتاريخ ديسمبر 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                M.M.R II®  
powder and solvent for suspension for injection
Measles, mumps, and rubella vaccine (live)


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                After reconstitution, one dose (0.5 ml) contains:

Measles virus1 Enders’ Edmonston strain (live, attenuated) ………..….not less than 1x103 CCID50*
Mumps virus1 Jeryl Lynn™ [Level B] strain (live, attenuated)……...…not less than 12.5x103 CCID50*
Rubella virus2 Wistar RA 27/3 strain (live, attenuated) …………….….not less than 1x103 CCID50*

*50% cell culture infectious dose

1 produced in chick embryo cells.
2 produced in WI-38 human diploid lung fibroblasts.

The vaccine may contain traces of recombinant human albumin (rHA). 
This vaccine contains a trace amount of neomycin. See section 4.3.

Excipients with known effect:
The vaccine contains 14.5 mg of sorbitol. See section 4.4.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for suspension for injection.
Before reconstitution, the powder is a light yellow compact crystalline cake and the solvent is a clear colourless fluid.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>M.M.R II is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals from 12&nbsp;months of age (see section&nbsp;4.2).</p><p>&nbsp;</p><p>M.M.R II can be administered to infants from 9 months of age under special circumstances (see sections 4.2, 4.4 and 5.1).</p><p><strong>&nbsp;</strong></p><p>For use in measles outbreaks, or for post-exposure vaccination, or, for use in previously unvaccinated individuals older than 9&nbsp;months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella, see section&nbsp;5.1.</p><p>&nbsp;</p><p>M.M.R II is to be used on the basis of official recommendations.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>&nbsp;</em></p><p><u>Individuals 12&nbsp;months of age or older:</u></p><p>Individuals 12&nbsp;months or older should receive one dose at an elected date. A second dose may be administered at least 4&nbsp;weeks after the first dose in accordance with official recommendation. The second dose is intended for individuals who did not respond to the first dose for any reason.</p><p><u>&nbsp;</u></p><p><u>Infants between 9&nbsp;and 12&nbsp;months of age:</u></p><p>Immunogenicity and safety data show that M.M.R II can be administered to infants between 9 and 12&nbsp;months of age, in accordance with official recommendations or when an early protection is considered necessary (e.g., day-care, outbreak situations, or travel to a region with high prevalence of measles). Such infants should be revaccinated at 12 to 15 months. An additional dose with a measles‑containing vaccine should be considered according to official recommendations (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p><u>Infants below 9&nbsp;months of age:</u></p><p>No data on the efficacy and safety of M.M.R II for use in children below 9&nbsp;months of age are currently available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>The vaccine is to be injected intramuscularly (IM) or subcutaneously (SC).</p><p>&nbsp;</p><p>The preferred injection sites are the anterolateral area of the thigh in younger children and the deltoid area in older children, adolescents, and adults.</p><p>The vaccine should be administered subcutaneously in patients with thrombocytopenia or any coagulation disorder.</p><p>&nbsp;</p><p>For precautions to be taken before handling or administering the medicinal product, and for instructions on reconstitution of the medicinal product before administration, see section 6.6.</p><p><u>&nbsp;</u></p><p><strong>DO NOT INJECT INTRAVASCULARLY.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                History of hypersensitivity to any measles, mumps, or rubella vaccine, or to any of the excipients, including neomycin (see sections 2, 4.4, and 6.1).

Pregnancy. Furthermore, pregnancy should be avoided for 1 month following vaccination (see section 4.6).

Vaccination should be postponed during any illness with fever >38.5°C.

Active untreated tuberculosis. Children under treatment for tuberculosis have not experienced exacerbation of the disease when immunized with live measles virus vaccine. No studies have been reported to date on the effect of measles virus vaccines on children with untreated tuberculosis.

Blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic systems.

Current immunosuppressive therapy (including high doses of corticosteroids). M.M.R II is not contraindicated in individuals who are receiving topical or low dose parenteral corticosteroids (e.g. for asthma prophylaxis or replacement therapy).

Severe humoral or cellular (primary or acquired) immunodeficiency, e.g. severe combined immunodeficiency, agammaglobulinemia and AIDS or symptomatic HIV infection or an age-specific CD4+ T-lymphocyte percentage in children below 12 months: CD4+ <25% %; children between 12-35 months: CD4+ < 20%; children between 36-59 months: CD4+ < 15% (see section 4.4). 

In severely immunocompromised individuals inadvertently vaccinated with measles containing vaccine, measles inclusion body encephalitis, pneumonitis, and fatal outcome as a direct consequence of disseminated measles vaccine virus infection have been reported.

Family history of congenital or hereditary immunodeficiency, unless the immune competence of the potential vaccine recipient is demonstrated.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p>As with all injectable vaccines, appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the vaccine (see section 4.8).</p><p>&nbsp;</p><p>Adults and adolescents with a history of allergies may potentially be at increased risk of anaphylaxis or anaphylactoid reactions. Close monitoring is recommended following vaccination for the early signs of such reactions.</p><p>&nbsp;</p><p>Since live measles vaccine and live mumps vaccine are produced in chick embryo cell culture, persons with a history of anaphylactic, anaphylactoid, or other immediate reactions (e.g. hives, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) subsequent to egg ingestion may be at an enhanced risk of immediate-type hypersensitivity reactions. The potential risk-to-benefit ratio should be carefully evaluated before considering vaccination in such cases.</p><p>&nbsp;</p><p>Due caution should be employed in administration of M.M.R II to persons with individual or family history of convulsions, or a history of cerebral injury. The physician should be alert to the temperature elevation that may occur following vaccination (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Infants from 9 to 12 months of age vaccinated with a measles-containing vaccine during measles outbreaks or for other reasons may fail to respond to the vaccine due to the presence of circulating antibodies of maternal origin and/or immaturity of the immune system (see sections 4.2 and 5.1).</p><p>&nbsp;</p><p><u>Thrombocytopenia</u></p><p>This vaccine should be given subcutaneously to individuals with thrombocytopenia or any coagulation disorder because bleeding may occur following an intramuscular administration in these individuals.</p><p>Individuals with current thrombocytopenia may develop more severe thrombocytopenia following vaccination. In addition, individuals who experienced thrombocytopenia with the first dose of M.M.R II &nbsp;(or its component vaccines) may develop thrombocytopenia with repeat doses. Serologic status may be evaluated to determine whether or not additional doses of vaccine are needed. The potential risk‑to‑benefit ratio should be carefully evaluated before considering vaccination in such cases (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Other</u></p><p>Vaccination may be considered in patients with selected immune deficiencies where the benefits outweigh the risks (asymptomatic HIV patients, IgG subclass deficiencies, congenital neutropenia, chronic granulomatous disease, and complement deficiency diseases).</p><p>&nbsp;</p><p>Immunocompromised patients who have no contraindication for this vaccination (see section 4.3) may not respond as well as immunocompetent patients; therefore, some of these patients may acquire</p><p>&nbsp;</p><p>measles, mumps, or rubella in case of contact, despite appropriate vaccine administration. These patients should be monitored carefully for signs of measles, parotitis, and rubella.</p><p>Vaccination with M.M.R II may not result in protection in all vaccinees.</p><p>&nbsp;<u>Transmission</u></p><p>Excretion of small amounts of the live attenuated rubella virus from the nose or throat has occurred in the majority of susceptible individuals 7 to 28 days after vaccination. There is no confirmed evidence to indicate that such virus is transmitted to susceptible persons who are in contact with the vaccinated individuals. Consequently, transmission through close personal contact, while accepted as a theoretical possibility, is not regarded as a significant risk; however, transmission of the rubella vaccine virus to infants via breast milk has been documented without any evidence of clinical disease (see section 4.6).</p><p>&nbsp;</p><p>There are no reports of transmission of the more attenuated Enders&rsquo; Edmonston strain of measles virus or the Jeryl Lynn&trade; strain of mumps virus from vaccinees to susceptible contacts.</p><p>&nbsp;</p><p><u>Sodium</u></p><p>This medicinal product contains less than 1 mmol sodium (23 milligrams) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p><u>Potassium</u></p><p>This medicinal product contains less than 1 mmol potassium (39 milligrams) per dose, that is to say essentially &lsquo;potassium-free&rsquo;.</p><p>&nbsp;</p><p><u>Sorbitol (E 420)</u></p><p>This medicinal product contains 14.5 milligrams of sorbitol per dose. The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account.</p><p>&nbsp;</p><p><u>Interference with laboratory tests:</u> see section 4.5.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Immune globulin</u></p><p>Immune globulin (IG) is not to be given concomitantly with M.M.R II.</p><p>&nbsp;</p><p>Administration of immune globulins concomitantly with M.M.R II may interfere with the expected immune response. Vaccination should be deferred for at least 3&nbsp;months following blood or plasma transfusions, or administration of human immune serum globulin.</p><p>&nbsp;</p><p>Administration of measles, mumps, or rubella antibody‑containing blood products, including immune globulin preparations, should be avoided within 1&nbsp;month after a dose of M.M.R II unless considered to be essential.</p><p>&nbsp;</p><p><u>Laboratory tests</u></p><p>It has been reported that live attenuated measles, mumps, and rubella virus vaccines given individually may result in a temporary depression of tuberculin skin sensitivity. Therefore, if a tuberculin test is to be done, it should be administered either any time before, simultaneously with, or 4&nbsp;to&nbsp;6&nbsp;weeks after vaccination with M.M.R II.</p><p>&nbsp;</p><p><u>Use with other vaccines</u></p><p>Currently no specific studies have been conducted on the concomitant use of M.M.R II and other vaccines. However, since M.M.R II has been shown to have safety and immunogenicity profiles similar to the previous formulation of the combined measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc., experience with this vaccine can be considered.</p><p>&nbsp;</p><p>Published clinical data support concomitant administration of the previous formulation of the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. with other childhood vaccinations, including DTaP (or DTwP), IPV (or OPV), HIB (<em>Haemophilus influenzae</em> type b), HIB-HBV (<em>Haemophilus influenzae</em> type b with Hepatitis B vaccine), and VAR (varicella). M.M.R II should be given concomitantly at separate injection sites, or one month before or after administration of other live virus vaccines.</p><p>&nbsp;</p><p>Based on clinical studies with the quadrivalent measles, mumps, rubella and varicella vaccine and with the previous formulation of the combined measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc., M.M.R II can be given simultaneously (but at separate injection sites) with Prevenar and/or&nbsp;hepatitis A vaccine. In these clinical studies, it was demonstrated that the immune responses were unaffected and that the overall safety profiles of the administered vaccines were similar.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Pregnant women should not be vaccinated with M.M.R II.</p><p>&nbsp;</p><p>Studies have not been conducted with M.M.R II in pregnant women.</p><p>&nbsp;</p><p>In a review of more than 3500&nbsp;susceptible women who were unknowingly in early stages of pregnancy when vaccinated with a rubella‑containing vaccine, no cases of congenital rubella syndrome were reported. Subsequent post-marketing surveillance identified congenital rubella syndrome associated with a rubella vaccine strain following inadvertent vaccination of a pregnant woman with a measles, mumps and rubella vaccine.</p><p>&nbsp;</p><p>Foetal damage has not been documented when measles or mumps vaccines have been given to pregnant women.</p><p>&nbsp;</p><p>Inadvertent vaccination of unknowingly pregnant women with measles-, mumps-, or rubella‑containing vaccines should not be a reason for termination of pregnancy.</p><p>&nbsp;</p><p>Pregnancy should be avoided for 1&nbsp;month following vaccination. Women who intend to become pregnant should be advised to delay.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Studies have shown that breast‑feeding postpartum women vaccinated with live attenuated rubella vaccines may secrete the virus in breast milk and transmit it to breast‑fed infants. In the infants with serological evidence of rubella infection, none had symptomatic disease. It is not known whether measles or mumps vaccine virus is secreted in human milk; therefore, caution should be exercised when M.M.R II is administered to a breast‑feeding woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>M.M.R II has not been evaluated in fertility studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. M.M.R II &nbsp;is expected to have no or negligible influence on ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>a. Summary of the safety profile</u></p><p>In clinical trials, M.M.R II was administered to 1965&nbsp;children (see section&nbsp;5.1), and the general safety profile was comparable to the previous formulation of the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc.</p><p>&nbsp;</p><p>In a clinical trial, 752 children received M.M.R II, either intramuscularly or subcutaneously. The general safety profile of either administration routes were comparable, although injection-site reactions were less frequent in the IM group (15.8%) compared with the SC group (25.8%).</p><p>&nbsp;</p><p>All adverse reactions were evaluated in 1940&nbsp;children. Among these children, the vaccine‑related adverse reactions, summarised in section b, were observed in individuals following vaccination with M.M.R II (excluding isolated reports with frequency &lt;0.2%).</p><p>&nbsp;</p><p>In comparison to the first dose, a second dose of M.M.R II is not associated with an increase in the incidence and severity of clinical symptoms including those suggestive of hypersensitivity reaction.</p><p>&nbsp;</p><p>Additionally, other adverse reactions reported with post-marketing use of M.M.R II and/or in clinical studies and post-marketing use of previous formulations of monovalent and of the combined measles, mumps, and rubella vaccines manufactured by Merck &amp; Co., Inc. without regard to causality or frequency are available and are summarised in section b. The frequency of these adverse events is qualified as &quot;not known&quot; when it cannot be estimated based on the available data. These data were reported based on more than 400&nbsp;million doses distributed worldwide.</p><p>&nbsp;</p><p>The most common adverse reactions reported with the use of M.M.R II were: fever (38.5&deg;C or higher); injection site reactions including pain, swelling and erythema.</p><p>&nbsp;</p><p><u>b. Tabulated list of adverse reactions</u></p><p>Adverse reactions are ranked under headings of frequency using the following convention:</p><p>[Very common (&ge;1/10); Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &le;1/100); Not known (cannot be estimated from the available data)]</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:441px"><tbody><tr><td style="width:244.15pt"><p>Adverse reactions</p></td><td style="width:86.8pt"><p>Frequency</p></td></tr><tr><td colspan="2" style="background-color:#cccccc; width:330.95pt"><p><em>Infections and infestations</em></p></td></tr><tr><td style="width:244.15pt"><p>Nasopharyngitis, Upper respiratory tract infection or Viral infection</p></td><td style="width:86.8pt"><p>Uncommon</p></td></tr><tr><td style="width:244.15pt"><p>Aseptic meningitis<sup>&dagger;</sup>, Atypical measles, Epididymitis, Orchitis, Otitis media, Parotitis, Rhinitis, Subacute Sclerosing Panencephalitis<sup>&dagger;</sup></p></td><td style="width:86.8pt"><p>Not known</p></td></tr><tr><td colspan="2" style="background-color:#cccccc; width:330.95pt"><p><em>Blood and the lymphatic system disorders</em></p></td></tr><tr><td style="width:244.15pt"><p>Regional lymphadenopathy, Thrombocytopenia</p></td><td style="width:86.8pt"><p>Not known</p></td></tr><tr><td colspan="2" style="background-color:#cccccc; width:330.95pt"><p><em>Immune system disorders</em></p></td></tr><tr><td style="width:244.15pt"><p>Anaphylactoid reaction, Anaphylaxis and related phenomenon such as Angioneurotic oedema, Facial oedema, and Peripheral oedema</p></td><td style="width:86.8pt"><p>Not known</p></td></tr><tr><td colspan="2" style="background-color:#cccccc; width:330.95pt"><p><em>Psychiatric disorders</em></p></td></tr><tr><td style="width:244.15pt"><p>Irritability</p></td><td style="width:86.8pt"><p>Not known</p></td></tr><tr><td colspan="2" style="background-color:#cccccc; width:330.95pt"><p><em>Nervous system disorders</em></p></td></tr><tr><td style="width:244.15pt"><p>Afebrile convulsions or seizures, Ataxia, Dizziness, Encephalitis<sup>&dagger;</sup> , Encephalopathy<sup>&dagger;</sup> , Febrile convulsion (in children), Guillain‑Barre syndrome, Headache, Measles inclusion body encephalitis (MIBE) (see section&nbsp;4.3), Ocular palsies, Optic neuritis, Paraesthesia, Polyneuritis, Polyneuropathy, Retrobulbar neuritis, Syncope</p></td><td style="width:86.8pt"><p>Not known</p></td></tr><tr><td colspan="2" style="background-color:#cccccc; width:330.95pt"><p><em>Eye disorders</em></p></td></tr><tr><td style="width:244.15pt"><p>Conjunctivitis, Retinitis</p></td><td style="width:86.8pt"><p>Not known</p></td></tr><tr><td colspan="2" style="background-color:#cccccc; width:330.95pt"><p><em>Ear and labyrinth disorders</em></p></td></tr><tr><td style="width:244.15pt"><p>Nerve deafness</p></td><td style="width:86.8pt"><p>Not known</p></td></tr><tr><td colspan="2" style="background-color:#cccccc; width:330.95pt"><p><em>Respiratory, thoracic, and mediastinal disorders</em></p></td></tr><tr><td style="width:244.15pt"><p>Rhinorrhoea</p></td><td style="width:86.8pt"><p>Uncommon</p></td></tr><tr><td style="width:244.15pt"><p>Bronchial spasm, Cough, Pneumonia, Pneumonitis (see section&nbsp;4.3), Sore throat</p></td><td style="width:86.8pt"><p>Not known</p></td></tr><tr><td colspan="2" style="background-color:#cccccc; width:330.95pt"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td style="width:244.15pt"><p>Diarrhoea or Vomiting</p></td><td style="width:86.8pt"><p>Uncommon</p></td></tr><tr><td style="width:244.15pt"><p>Nausea</p></td><td style="width:86.8pt"><p>Not known</p></td></tr><tr><td colspan="2" style="background-color:#cccccc; width:330.95pt"><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td style="width:244.15pt"><p>Rash morbilliform or other Rash</p></td><td style="width:86.8pt"><p>Common</p></td></tr><tr><td style="width:244.15pt"><p>Urticaria</p></td><td style="width:86.8pt"><p>Uncommon</p></td></tr><tr><td style="width:244.15pt"><p>Panniculitis, Pruritus, Purpura, Skin induration, Stevens‑Johnson syndrome.</p></td><td style="width:86.8pt"><p>Not known</p></td></tr><tr><td colspan="2" style="background-color:#cccccc; width:330.95pt"><p><em>Musculoskeletal, connective tissue and bone disorders</em></p></td></tr><tr><td style="width:244.15pt"><p>Arthritis<sup>&dagger;</sup> and/or Arthralgia<sup>&dagger;</sup> (usually transient and rarely chronic), Myalgia</p></td><td style="width:86.8pt"><p>Not known</p></td></tr><tr><td colspan="2" style="background-color:#cccccc; width:330.95pt"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td style="width:244.15pt"><p>Fever (38.5&deg;C or higher), Injection site erythema, Injection site pain, and Injection site swelling</p></td><td style="width:86.8pt"><p>Very common</p></td></tr><tr><td style="width:244.15pt"><p>Injection site bruising</p></td><td style="width:86.8pt"><p>Common</p></td></tr><tr><td style="width:244.15pt"><p>Injection site rash</p></td><td style="width:86.8pt"><p>Uncommon</p></td></tr><tr><td style="width:244.15pt"><p>Burning and/or Stinging of short duration at the injection site, Malaise, Papillitis, Peripheral oedema, Swelling, Tenderness, Vesicles at the injection site, Wheal and Flare at the injection site</p></td><td style="width:86.8pt"><p>Not known</p></td></tr><tr><td colspan="2" style="background-color:#cccccc; width:330.95pt"><p><em>Vascular disorders</em></p></td></tr><tr><td style="width:244.15pt"><p>Vasculitis</p></td><td style="width:86.8pt"><p>Not known</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>&dagger;</sup> see section c</p><p>&nbsp;</p><p><u>c. Description of selected adverse reactions</u></p><p><u>Aseptic meningitis</u></p><p>Cases of aseptic meningitis have been reported following measles, mumps, and rubella vaccination. Although a causal relationship between other strains of mumps vaccine and aseptic meningitis has been shown, there is no evidence to link Jeryl Lynn&trade; mumps vaccine to aseptic meningitis.</p><p>&nbsp;</p><p><u>Encephalitis and Encephalopathy</u></p><p>In severely immunocompromised individuals inadvertently vaccinated with measles-containing vaccine, measles inclusion body encephalitis, pneumonitis, and fatal outcome as a direct consequence of disseminated measles vaccine virus infection have been reported (see section 4.3); disseminated mumps and rubella vaccine virus infection has also been reported.</p><p><u>&nbsp;</u></p><p><u>Subacute sclerosing panencephalitis</u><u> </u></p><p>There is no evidence that measles vaccine can cause SSPE. There have been reports of SSPE in children who did not have a history of infection with wild-type measles but did receive measles vaccine. Some of these cases may have resulted from unrecognized measles in the first year of life or possibly from the measles vaccination. The results of a retrospective case‑controlled study conducted by the US Centers for Disease Control and Prevention suggest that the overall effect of measles vaccine has been to protect against SSPE by preventing measles with its inherent risk of SSPE.</p><p>&nbsp;</p><p><u>Arthralgia and/or arthritis</u></p><p>Arthralgia and/or arthritis (usually transient and rarely chronic), and polyneuritis are features of infection with wild-type rubella and vary in frequency and severity with age and sex, being greatest in adult females and least in prepubertal children. Following vaccination in children, reactions in joints are generally uncommon (0‑3%) and of brief duration. In women, incidence rates for arthritis and arthralgia are generally higher than those seen in children (12‑20%), and the reactions tend to be more marked and of longer duration. Symptoms may persist for a matter of months or on rare occasions for years. In adolescent girls, the reactions appear to be intermediate in incidence between those seen in children and adult women. Even in older women (35‑45&nbsp;years), these reactions are generally well tolerated and rarely interfere with normal activities.</p><p>&nbsp;</p><p><u>Chronic arthritis</u></p><p>Chronic arthritis has been associated with wild‑type rubella infection and has been related to persistent virus and/or viral antigen isolated from body tissues. Only rarely have vaccine recipients developed chronic joint symptoms.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via: (The National Pharmacovigilance and Drug Safety Centre (NPC)).</p><p><strong>To report any side effect(s):</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Saudi Arabia: </u></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Administration of a higher than recommended dose of M.M.R II was reported rarely and the adverse reaction profile was comparable to that observed with the recommended dose of M.M.R II.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Viral vaccine, ATC code J07BD52</p><p>&nbsp;</p><p><u>Evaluation of immunogenicity and clinical efficacy</u></p><p>A comparative study in 1279&nbsp;subjects who received M.M.R II &nbsp;or the previous formulation (manufactured with human serum albumin) of the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. demonstrated similar immunogenicity and safety between the 2&nbsp;products.</p><p>&nbsp;</p><p>Clinical studies of 284&nbsp;triple seronegative children, 11&nbsp;months to 7&nbsp;years of age, demonstrated that the previous formulation of the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. is highly immunogenic and generally well tolerated. In these studies, a single injection of the vaccine induced measles hemagglutination-inhibition (HI) antibodies in 95%, mumps neutralising antibodies in 96%, and rubella HI antibodies in 99% of susceptible persons.</p><p>&nbsp;</p><p><u>Evaluation of immunogenicity in children from 9 to 12 months of age at the time of first dose</u></p><p>A clinical study was conducted with the quadrivalent measles, mumps, rubella and varicella vaccine manufactured by Merck &amp; Co., Inc., administered with a 2-dose schedule, the doses being given 3 months apart in 1,620 healthy subjects from 9 to 12 months of age at the time of first dose. The safety profile post-dose 1 and 2 was generally comparable for all age cohorts.</p><p>&nbsp;</p><p>In the Full Analysis Set (vaccinated subjects regardless of their antibody titre at baseline), high seroprotection rates of &gt;99% were elicited to mumps and rubella post-dose 2, regardless of the age of the vaccinee at the first dose. After 2 doses, the seroprotection rates against measles were 98.1% when the first dose was given at 11 months compared to 98.9% when the first dose was given at 12 months (non-inferiority study objective met). After two doses, the seroprotection rates against measles were 94.6% when the first dose was given at 9 months compared to 98.9% when the first dose was given at 12 months (non-inferiority study objective not met).</p><p>&nbsp;</p><p>The seroprotection rates to measles, mumps, and rubella for the Full Analysis Set are given in Table 1.</p><p>&nbsp;</p><p>Table 1: Seroprotection Rates to Measles, Mumps, and Rubella 6 Weeks Post-Dose 1 and 6 Weeks Post-Dose 2 of the quadrivalent measles, mumps, rubella and varicella vaccine manufactured by Merck &amp; Co., Inc. &ndash; Full Analysis Set</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="height:25.75pt; width:59.4pt"><p><strong>Valence (seropro</strong></p><p><strong>tection level)</strong></p></td><td rowspan="2" style="height:25.75pt; width:45.0pt"><p><strong>Time point</strong></p></td><td style="height:25.75pt; width:117.0pt"><p><strong>Dose 1 at 9 months / Dose 2 at 12 months</strong></p><p><strong>N = 527</strong></p></td><td style="height:25.75pt; width:117.0pt"><p><strong>Dose<s>&nbsp; </s>1 at 11 months / Dose 2 at 14 months</strong></p><p><strong>N = 480</strong></p></td><td style="height:25.75pt; width:117.0pt"><p><strong>Dose 1 at 12 months / Dose 2 at 15 months</strong></p><p><strong>N = 466</strong></p></td></tr><tr><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p><strong>Seroprotection rates<s> </s></strong></p><p><strong>[95% CI]</strong></p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p><strong>Seroprotection rates<s> </s></strong></p><p><strong>[95% CI]</strong></p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p><strong>Seroprotection rates [95% CI]</strong></p></td></tr><tr><td rowspan="2" style="height:25.75pt; width:59.4pt"><p><strong>Measles </strong><br />(titre &ge;255 mIU/mL)</p></td><td style="height:25.75pt; width:45.0pt"><p><strong>Post-Dose 1</strong></p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>72.3%<br />[68.2; 76.1]</p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>87.6%<br />[84.2; 90.4]</p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>90.6%<br />[87.6; 93.1]</p></td></tr><tr><td style="height:25.75pt; width:45.0pt"><p><strong>Post-Dose 2</strong></p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>94.6%<br />[92.3; 96.4]</p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>98.1%<br />[96.4; 99.1]</p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>98.9%<br />[97.5; 99.6]</p></td></tr><tr><td rowspan="2" style="height:25.75pt; width:59.4pt"><p><strong>Mumps </strong>(titre &ge;10 ELISA Ab units/mL)</p></td><td style="height:25.75pt; width:45.0pt"><p><strong>Post-Dose 1</strong></p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>96.4%<br />[94.4; 97.8]</p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>98.7%<br />[97.3; 99.5]</p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>98.5%<br />[96.9; 99.4]</p></td></tr><tr><td style="height:25.75pt; width:45.0pt"><p><strong>Post-Dose 2</strong></p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>99.2%<br />[98.0; 99.8]</p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>99.6%<br />[98.5; 99.9]</p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>99.3%<br />[98.1; 99.9]</p></td></tr><tr><td rowspan="2" style="height:25.75pt; width:59.4pt"><p><strong>Rubella</strong> (titre &ge;10 IU/mL)</p></td><td style="height:25.75pt; width:45.0pt"><p><strong>Post-Dose 1</strong></p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>97.3%<br />[95.5; 98.5]</p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>98.7%<br />[97.3; 99.5]</p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>97.8%<br />[96.0; 98.9]</p></td></tr><tr><td style="height:25.75pt; width:45.0pt"><p><strong>Post-Dose 2</strong></p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>99.4%<br />[98.3; 99.9]</p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>99.4%<br />[98.1; 99.9]</p></td><td style="height:25.75pt; vertical-align:top; width:117.0pt"><p>99.6%<br />[98.4; 99.9]</p></td></tr></tbody></table><p>&nbsp;</p><p>The post‑dose 2 geometric mean titres (GMTs) against mumps and rubella were comparable across all age categories, while the GMTs against measles were lower in subjects who received the first dose at 9 months of age as compared to subjects who received the first dose at 11 or 12 months of age.</p><p>&nbsp;</p><p>A comparative study in 752 subjects who received M.M.R II &nbsp;either by intramuscular route or subcutaneous route demonstrated a similar immunogenicity profile between both administration routes.</p><p>&nbsp;</p><p>The efficacy of the components of the previous formulation of the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. was established in a series of double‑blind controlled field trials, which demonstrated a high degree of protective efficacy afforded by the individual vaccine components. These studies also established that seroconversion in response to vaccination against measles, mumps, and rubella paralleled protection from these diseases.</p><p>&nbsp;</p><p><u>Post‑exposure vaccination</u></p><p>Vaccination of individuals exposed to wild‑type measles may provide some protection if the vaccine can be administered within 72&nbsp;hours after exposure. If, however, the vaccine is given a few days before exposure, substantial protection may be afforded. There is no conclusive evidence that vaccination of individuals recently exposed to wild‑type mumps or wild‑type rubella will provide protection.</p><p>&nbsp;</p><p><u>Effectiveness</u></p><p>More than 400&nbsp;million doses of the previous formulation of the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. have been distributed worldwide (1978&nbsp;to&nbsp;2003). Widespread use of a 2‑dose vaccination schedule in the United States and countries such as Finland and Sweden has led to a &gt;99% reduction in the incidence of each of the 3&nbsp;targeted diseases.</p><p>&nbsp;</p><p><u>Non-pregnant adolescent and adult females</u></p><p>Vaccination of susceptible non‑pregnant adolescent and adult females of childbearing age with live attenuated rubella virus vaccine is indicated if certain precautions are observed (see sections&nbsp;4.4 and 4.6). Vaccinating susceptible postpubertal females confers individual protection against subsequently acquiring rubella infection during pregnancy, which, in turn, prevents infection of the foetus and consequent congenital rubella injury.</p><p>&nbsp;</p><p>Previously unvaccinated individuals older than 9&nbsp;months who are in contact with susceptible pregnant women should receive live attenuated rubella‑containing vaccine (such as M.M.R II &nbsp;or a monovalent rubella vaccine) to reduce the risk of exposure of the pregnant woman.</p><p>&nbsp;</p><p><u>Individuals likely to be susceptible to mumps and rubella</u></p><p>M.M.R II &nbsp;is preferred for vaccination of persons likely to be susceptible to mumps and rubella. Individuals who require vaccination against measles can receive M.M.R II &nbsp;regardless of their immune status to mumps or rubella if a monovalent measles vaccine is not readily available.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical studies have not been conducted.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Powder</u></p><p>Sorbitol (14.5 mg)</p><p>Sodium phosphate, monobasic (3.1 mg)</p><p>Sodium phosphate, dibasic (2.2 mg)</p><p>Potassium phosphate, monobasic (20 &mu;g)</p><p>Potassium phosphate, dibasic (30 &mu;g)</p><p>Gelatin (Porcine) Hydrolyzed (14.5 mg)</p><p>Sucrose (1.9 mg)</p><p>Medium 199&nbsp; &nbsp;(3.3 mg)Minimum Essential Medium, Eagle &nbsp;(0.1 mg)</p><p>Monosodium L‑glutamate (20 &mu;g)</p><p>Neomycin (25 &mu;g)</p><p>Phenol red (3.4 &mu;g)</p><p>Sodium bicarbonate (0.5 mg)</p><p>Hydrochloric acid (to adjust pH)</p><p>Sodium hydroxide (to adjust pH)</p><p>&nbsp;</p><p><u>Solvent</u></p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, the vaccine must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.

After reconstitution, the vaccine should be used immediately; however, in use stability has been demonstrated for 8 hours when refrigerated at 2°C 8°C.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store and transport refrigerated (2&deg;C &ndash; 8&deg;C).</p><p>Do not freeze.</p><p>Keep the vial of powder in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after the reconstitution of the medicinal product, see section&nbsp;6.3</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder in a vial (glass) with a stopper (butyl rubber) and solvent in a vial (glass) with stopper (chlorobutyl rubber) in a pack size of 1 and 10.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To reconstitute, use the solvent supplied. The solvent is a clear colourless liquid. Before mixing with the solvent, the powder is a light yellow compact crystalline cake. When completely reconstituted, the vaccine is a clear yellow liquid.</p><p>&nbsp;</p><p>It is important to use a separate sterile syringe and needle for each patient to prevent transmission of infectious agents from one individual to another.</p><p>&nbsp;</p><p><u>Reconstitution instructions</u></p><p>Withdraw the entire volume of solvent into a syringe to be used for reconstitution and injection. Inject the entire content of the syringe into the vial containing the powder. Gently agitate to mix thoroughly.</p><p>The reconstituted vaccine must not be used if any particulate matter is noted or if the appearance of the solvent or powder or of the reconstituted vaccine differs from that described above.</p><p>&nbsp;</p><p>Withdraw the entire content of the reconstituted vaccine vial into the same syringe and inject the entire volume.</p><p>&nbsp;</p><p>If two needles are provided: use one needle to reconstitute the vaccine and the other for its administration to the person to be vaccinated.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder:
Merck, Sharp & Dohme LLC, 770 Sumneytown Pike, P.O. Box 4, West Point, PA 19486, US.

Manufacturer:
Merck, Sharp & Dohme LLC, 770 Sumneytown Pike, P.O. Box 4, West Point, PA 19486, US.

And/ Or

Merck, Sharp & Dohme LLC, 5325 Old Oxford Road, Durham, NC 27712, US

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dec 2024



            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>